We used genome-wide single nucleotide polymorphism (SNP) data to search for the presence of copy number variants (CNVs) in 882 patients with bipolar disorder (BD) and 872 populationbased controls. A total of 291 (33%) patients had an early age-at-onset p21 years (AOp21years). We systematically filtered for CNVs that cover at least 30 consecutive SNPs and which directly affect at least one RefSeq gene. We tested whether (a) the genome-wide burden of these filtered CNVs differed between patients and controls and whether (b) the frequency of specific CNVs differed between patients and controls. Genome-wide burden analyses revealed that the frequency and size of CNVs did not differ substantially between the total samples of BD patients and controls. However, separate analysis of patients with AOp21years and AO > 21years showed that the frequency of microduplications was significantly higher (P = 0.0004) and the average size of singleton microdeletions was significantly larger (P = 0.0056) in patients with AOp21years compared with controls. A search for specific BD-associated CNVs identified two common CNVs: (a) a 160 kb microduplication on 10q11 was overrepresented in AOp21years patients (9.62%) compared with controls (3.67%, P = 0.0005) and (b) a 248 kb microduplication on 6q27 was overrepresented in the AOp21years subgroup (5.84%) compared with controls (2.52%, P = 0.0039). These data suggest that CNVs have an influence on the development of early-onset, but not later-onset BD. Our study provides further support for previous hypotheses of an etiological difference between early-onset and later-onset BD.
Introduction
Bipolar disorder (BD) is a common, severe mood disorder that is characterized by recurring episodes of extreme exaltation (mania) and depression. Mood symptoms are often accompanied by disturbances in thinking and behavior. BD has a lifetime risk in the general population of 0.5-1.5%. 1 Twin, family and adoption studies have provided strong evidence for a genetic predisposition to BD. 2, 3 Heritability has been estimated to be between 60 and 85%. 4 Changes in the copy number of submicroscopic chromosomal segments, known as copy number variants (CNVs), are a major component of the difference between human genomes. 5 Based on their frequency, rare ( < 1%) and common (X1%) CNVs can be distinguished. Several recent studies have shown a strong influence of rare CNVs on the development of neuropsychiatric phenotypes such as autism 6, 7 and schizophrenia. [8] [9] [10] To date, only a limited number of studies have been published for BD. [11] [12] [13] [14] [15] Lachman et al. 11 investigated a mixed cohort of Caucasian patients and controls from the Czech Republic and the United States, and found that microdeletions and microduplications, affecting the gene glycogen synthase kinase 3 beta (GSK3B) were significantly increased in patients. Zhang et al. investigated singleton microdeletions (that is, those occurring only once in the total data set of patients and controls) of > 100 kb in their European American sample of 1 001 BD patients and 1 034 controls, and found that they were overrepresented in patients. 12 Recently, Yang et al. published a study of a three-generation older Amish pedigree with segregating affective disorder. 13 They reported that a set of four CNVs on chromosomes 6q27, 9q21, 12p13 and 15q11 were enriched in affected family members, and that these altered the expression of neuronal genes. Grozeva et al.
14 screened a sample of 1 868 patients with BD and 2 938 controls for large ( > 100 kb) and rare (found in < 1% of the population) CNVs. No specific CNV was associated with BD, and the authors found no increased genome-wide burden of CNVs in patients compared with controls. The Wellcome Trust Case Control Consortium (WTCCC 15 ) investigated common CNVs (found in > 5% of the population) of > 0.5 kb in a sample of 2 007 patients with BD and 3 000 controls, and found no association between CNVs and the disease.
In the present study, we screened the genome-wide single nucleotide polymorphism (SNP) data of 882 patients with BD and 872 population-based controls for predicted common and rare CNVs using more than 540 000 autosomal and X-chromosomal markers. All study participants were of German descent. We tested both the overall group of BD patients and a subgroup with an age-at-onset of p21 years as several studies have suggested that early-onset BD patients may represent a clinically and genetically more homogeneous subtype of BD. Clinical studies have demonstrated that early-onset BD is a more severe form of the disorder that is characterized by frequent psychotic features, more mixed episodes, greater psychiatric co-morbidity and poorer response to prophylactic lithium treatment. [16] [17] [18] Familial aggregation is more pronounced in relatives of early-onset BD patients than in relatives of later-onset BD patients. [16] [17] [18] [19] [20] Finally, the findings of several studies have suggested the existence of an intra-familial correlation for ageat-onset among bipolar siblings, 21, 22 and a segregation analysis has shown that BD is transmitted differentially in early-and later-onset BD families. 20 To control for the number of technical artifacts, we developed a stringent protocol for quality control (QC) and filtering. On the basis of these data, we conducted statistical tests for the genome-wide burden of CNVs and for all specific common and rare CNVs that were found to be associated with BD.
Materials and methods

Sample description
Unrelated patients with a clinical history of BD (post QC: type I, n = 767; type II, n = 102; not other specified, n = 13) were recruited at two centers: the Central Institute of Mental Health, Mannheim and the Department of Psychiatry and Psychotherapy of the University of Bonn. The study was approved by the Institutional Review Boards, and all patients provided written informed consent before inclusion. DSM-IV lifetime diagnoses of BD were assigned using a consensus best-estimate procedure that was based on all available information including the findings of a structured SCID-I interview. 23 The same set of instruments was used by both centers. 24 Age-at-onset (AO) was defined as the age at which the first DSM-IV-criteria episode of either depression or mania had occurred. Post QC, the mean age of patients at the time of recruitment was 44.03 years with a standard deviation (s.d.) of 13.41, the mean age-at-onset was 27.90 years (s.d. = 11.28; median = 24; mode = 19). The AO distribution of the total sample deviated to the right of the Gaussian distribution (KolmogorovSmirnov Z = 5.10; P < 0.001; positive skewness = 1.10). The male/female ratio was 0.47.
Determining the cutoff point for early age-at-onset Despite extensive debate over the past decade, no consensus has yet been reached concerning the cutoff point for the definition of early and late AO in BD. Authors who have applied the same expectationmaximization algorithm to different samples have described divergent cutoffs for the definition of the early AO. Some have reported that a three-AO-group distribution best fitted their data 25, 26 and others a two-AO-group distribution. 27 This demonstrates that the results of an admixture analysis are sample dependent.
We therefore performed a commingling analysis in the present sample before selecting the cutoff point for the definition of early AO. We used the SEGREGsubroutine of the software S.A.G.E. (version 6.1, http://darwin.cwru.edu/sage/). 28 Commingling analysis reveals the distribution mixture of a trait through segregation analysis while allowing for ascertainment correction. Class D models are used as the regressive models in commingling analysis, which assume that the trait under investigation in the study probands is not conditional upon the trait in antecedent family members. The model that fitted the data best was selected on the basis of the smallest value of the Akaike information criterion.
Although the two-AO-group and the three-AOgroup models had fitted our data equally well in a preliminary analysis of a larger sample, 29 the best model in the present sample was a two-AO-group distribution. Before QC, the mean AO in the early DNA extraction, genotyping and quality control Venous blood samples were collected from all patients and controls. Lymphocyte DNA was extracted either by salting out with saturated sodium chloride solution 32 or by a Chemagic Magnetic Separation Module I (Chemagen, Baesweiler, Germany) according to the manufacturer 0 s recommendations. Individuals were genotyped using Illumina's HumanHap550v3 (HH550) or Human610-Quadv1 (H610Q) BeadArrays (San Diego, CA, USA). The genotype data had been generated as part of a genome-wide association study (GWAS) of BD. 33 The H610Q chip contains B60 000 probes and SNPs more than the HH550 array. The majority of the excess content represents non-polymorphic CNV probes, which leads to an excess of CNV calls for individuals genotyped on the H610Q chip (data not shown). To avoid such a bias, we only analyzed SNPs that are present on both chips, that is, a total of 541 524 SNPs (post QC).
Before computational CNV prediction, stringent QC criteria were applied to the genotype data at both the marker and the individual level. SNPs with a call rate of < 98% were excluded. Individuals were excluded for the following reasons: (a) DNA call rate < 97% (20 patients); (b) differences between Xchromosomally inferred and phenotypic sex (six patients); (c) DNA sample doublets identified by identity-by-state estimates (defined as IBS = 2.0, two controls); (d) relatedness of individuals (1.6pIBS < 2.0, no individual excluded); and (e) population outlier according to multi-dimensional scaling with HapMap phase 2 (one patient and three controls were excluded before the present CNV study).
CNV detection
CNVs were predicted using the program QuantiSNP (version 1.1, http://www.well.ox.ac.uk/QuantiSNP). 34 The algorithm implemented in QuantiSNP uses an Objective Bayes Hidden-Markov Model to estimate the copy number. To evaluate the presence of a CNV, QuantiSNP uses the normalized intensity data (that is log R ratio) and allele frequency data (i.e. B allele frequency) of each SNP. Both values were calculated by Illumina's BeadStudio Genotyping module (version 3.3.7, http://www.illumina.com/ pages.ilmn?ID = 169). Individuals were excluded if their s.d. from the log R ratio or their B allele frequency exceeded certain thresholds: log R ratio > 0.36 or B allele frequency > 0.12 (22 patients, six controls). We employed the normalization procedure for local GC content implemented in QuantiSNP to improve the accuracy of detection. The log Bayes Factor was computed for each CNV. This factor indicates the confidence of each predicted CNV, with higher values indicating higher statistical reliability.
To minimize the number of false-positive CNV calls, we only considered CNVs with a log Bayes Factor X30, that spanned a minimum of 30 consecutive SNPs, and which directly affect at least one RefSeq gene. 35 After applying these filters, we also excluded individuals with more than seven CNVs, as they were extreme outliers in terms of the number of CNV events (27 patients). Following quality control, 1044 CNV calls from a total of 882 BD patients and 872 controls were statistically analyzed. A total of 291 of the patients (33%) had an AOp21 years, and 591 patients had an AO > 21 years.
To confirm our QuantiSNP-based CNV results, we additionally screened our data set with PennCNV. 36 Both PennCNV and QuantiSNP apply a HiddenMarkov Model to estimate the copy number of an individual. They also take the log R ratio and B allele frequency of each SNP into account, and correct for GC content. The CNV data of both algorithms are available upon request.
Statistical analysis of CNV burden and specific CNVs
All association tests for genome-wide CNV burden and association of specific CNVs were performed using PLINK (version 1.06, http://pngu.mgh.harvard. edu/purcell/plink/). 37 We conducted the burden tests for CNV frequency (PROP, RATE) as well as for CNV length (TOTKB, AVGKB), that is, the total number of CNVs in patients vs controls (RATE); proportion of individuals with one or more CNVs in patients vs controls (PROP); total length spanned by CNVs per individual in the patient group vs the control group (TOTKB) and average size of CNVs per individual in the patient group vs the control group (AVGKB). All P-values were generated using 50 000 permutations.
We defined three major comparison groups for the genome-wide burden analyses:
1. All patients vs all controls 2. AOp21years patients vs controls 3. AO > 21years patients vs controls.
We tested each of these three comparison groups for six different categories of CNVs:
1. All CNVs 2. Microduplications 3. Microdeletions 4. All singleton CNVs 5. Singleton microduplications 6. Singleton microdeletions.
We performed a total of four different burden tests (RATE, PROP, TOTKB and AVGKB) in 18 test groups, that is, three major comparison groups for the six different categories of CNVs as described above, resulting in a total of 72 tests for association between CNV burden and BD. To account for all 72 tests, we also applied Bonferroni's method, although this procedure may be too conservative given that the tests were not independent of each other.
In addition, we monitored the distribution of CNVs in chromosomal regions 1q21, 2p16, 7q34-36, 15q11, 15q13, 16p11, 17p12 and 22q11, which have previously been reported to be associated with a variety of neuropsychiatric disorders ( Table 2) . As the borders of these regions are known, we relaxed our filter criteria, that is, we included all CNVs with log Bayes Factor X10, which were visually inspected by two independent investigators regardless of the number of affected SNPs. Association tests for these CNVs were performed using Fisher's exact test.
Verification of specific CNVs
All CNVs identified by QuantiSNP and PennCNV that had been found to be associated with neuropsychiatric disorders in previous studies, or which were located within chromosomal regions associated with BD, were visually inspected using Illumina's GenomeStudio.
The specific CNVs that were found to be associated with BD in the present study (6q27 and 10q11) were verified by quantitative real-time PCR (quantitative PCR) using TaqMan Copy Number Assays (Applied Biosystem, Foster City, CA, USA). We confirmed each CNV carrier by quantitative PCR and also tested non-CNV carriers (as defined by QuantiSNP and PennCNV) to detect possible CNV carriers who had not been identified by QuantiSNP and PennCNV. The status of all CNV carriers was confirmed by quantitative PCR, and no CNV carriers were detected among the putative non-CNV carriers tested. Copy numbers were calculated using the DDCt method implemented in the CopyCaller Software (v1.0, http://www. appliedbiosystems.com/support/software/copycaller/).
Analysis of pathways and biological processes
We analyzed whether genes affected by CNVs were enriched in certain pathways or biological processes using the web-based program Ingenuity Pathways Analysis platform (IPA, version 8.0, http://www. ingenuity.com). IPA is based on functional annotation and molecular interactions. Gene lists were assembled using RefSeq genes that are affected by the CNVs identified in the burden analysis (microduplications, singleton microdeletions). Lists were uploaded into IPA and investigated using the 'core analysis' function and default settings. In the functional analysis, biological functions were grouped into different categories from the Ingenuity knowledge base. To calculate the statistical significance of pathways and biological processes assigned to gene sets, P-values of the Fisher's exact test were corrected by the Benjamini-Hochberg method.
Results
We systematically analyzed our samples for significant genome-wide differences in the distribution of all CNVs between patients and controls (genomewide burden tests) as well as for a significant overrepresentation of specific CNVs in patients or controls. We examined the distribution of the number of CNVs per individual and identified a total of 27 extreme outliers in terms of CNV observations, with more than seven CNVs being detected in each individual. The samples of a total of 24 of these individuals were clustered in the outer rows of the same 96-well plate, and thus these findings are likely to represent plate effects. These individuals were excluded from the downstream analyses.
General description of the CNV data set
Association analysis for genome-wide CNV burden Overall, 10 of the 72 genome-wide burden tests revealed nominally significant differences in CNV burden between patients and controls. In the following, we provide a detailed description of the most important findings, as outlined in Table 1 .
All patients vs controls. In the total sample of 882 BD patients and 872 controls, the genome-wide burden of singleton microdeletions showed nominally significant association for two out of the four tests performed. The average total length of all singleton microdeletions per individual was 487.6 kb in patients compared with 265.1 kb in controls (TOTKB: P = 0.014). The average size per singleton microdeletion SNP-based search for CNVs in bipolar disorder L Priebe et al was 472.6 kb in patients and 249.3 kb in controls (AVGKB: P = 0.014). The PROP-and RATE-tests generated no significant P-values.
Patients with an early AO vs controls. When comparing the 291 AOp21years patients with all controls, we again found that singleton microdeletions in patients were, on average, larger (661.7 kb in AOp21years patients vs 249.3 kb in controls, AVGKB: P = 0.0056) and spanned longer chromosomal regions per individual than in controls (679.6 kb in AOp21-years patients vs 261.2 kb in controls, TOTKB: P = 0.0084). Furthermore, we observed that the total proportion of individuals with at least one microduplication (44.3% in AOp21years patients vs 33.1% in controls, PROP: P = 0.00040), at least one CNV (52.9% in AOp21years patients vs 42.3% in controls, PROP: P = 0.00092), or at least one singleton microduplication (17.2% in AOp21years patients vs 11.9% in controls, PROP: P = 0.017) was significantly higher in this BD subgroup. The PROP test P-value for microduplications, which was the most significant of all of the burden analyses, withstood correction for multiple testing with the Bonferroni method, which accounted for the number of all the tests performed in this study (n = 72, P adjusted = 0.029). However, there were no significant differences in the proportion of individuals who carried either microdeletions or singleton microdeletions.
Patients with AO > 21years vs controls. In the third test group, we analyzed the burden of CNVs in the AO > 21years subgroup (n = 591) vs all controls. These tests revealed no significant differences in CNV burden between patients and controls.
Association analyses of specific CNVs
We identified two common microduplications that were significantly overrepresented in patients compared with controls: (a) a 248 kb microduplication on chromosome 6q27 and (b) a 160 kb microduplication on chromosome 10q11 (Figure 1) .
The 10q11 microduplication (Figure 1a ) was observed in 53 patients (6.01%) and in 32 controls (3.67%, P = 0.035, odds ratio (OR) (95% confidence interval = 1.53 (1.05-2.72)). Of these 53 patients, 28 belong to the AOp21years subgroup (9.62% in AOp21years patients vs 3.67% in controls, P = 0.00052, OR (95% confidence interval) = 2. 79  (1.59-4.89) ). Following genome-wide correction 
Abbreviations: AOp21years, early age-at-onset patients; AO > 21years, patients with an age-at-onset later than 21 years; AVGKB, average size spanned by CNVs; BD, bipolar disorder; CNV, copy number variant; con, controls; P, P-value of which only values < 0.1 are shown; pat, patients; PROP, proportion of individuals with at least one CNV; RATE, number of CNVs per individual; TOTKB, total length spanned by CNVs. a Withstood Bonferroni correction for 72 tests, P adjusted = 0.029.
using permutation, this P-value remained significant (n = 50 000; P adjusted = 0.032). In view of the genetic marker resolution provided by our approach, all observed microduplications at the 10q11 locus appear to have the same breakpoints (length B160 kb, chr10: 47.01-47.17 Mb, NCBI build 36), and carry 30 consecutive SNPs. This CNV covers the complete gene anthrax toxin receptor-like gene (ANTXRL). The microduplication on chromosome 6q27 ( Figure  1b) was detected in 17 patients from the AOp21 years subgroup (5.84%) and in 22 controls (2.52%, P = 0.0039, OR (95% confidence interval) = 2.40 (1.18-4.80)). There were no significant differences in distribution when all BD patients were compared with controls. In CNV carriers, slight differences in CNV size were observed, with a shared overlap of around 248 kb (chr6: 168.09-168.33 Mb, NCBI build 36) that was due to 110 adjacent SNPs. Three genes are affected by this microduplication: (a) kinesin family member 25 (KIF25), (b) FERM domain On 6q27, the microduplications were characterized by six different possible breakpoints in early-onset BD patients (AOp21years, blue bars) and controls (green bars), leading to a shared sequence of nearly 248 kb (gray bar). These duplications were observed in 17 of 291 AOp21years patients and in 22 of 872 controls. The 6q27 CNVs overlapped with the 3 0 terminus of MLLT4 as well as with the complete sequences of KIF25 and FRMD1. DACT2, a WNT signaling pathway gene, is located around 115 kb downstream of this CNV. CNVs in patients and controls were sorted according to their length. Schematic drawings were generated using UCSC Genome browser (NCBI Build 36.1).
SNP-based search for CNVs in bipolar disorder
L Priebe et al containing 1 (FRMD1) and (c) parts of the 3 0 terminus of mixed-lineage leukemia translocated to 4 (MLLT4). The gene dapper, antagonist of beta-catenin, homolog 2 (DACT2) lies around 115 kb downstream from this common microduplication. DACT2 participates in the WNT signaling pathway, 38, 39 which is known to regulate neurogenesis and neuroprotection.
In a follow-up analysis, we tested whether patients carrying either the common CNVs on 6q27 or the CNV on 10q11 showed differences in sex distribution or family history of psychiatric disorder compared with patients who were non-carriers. No significant associations were observed for either phenotypic item (data not shown).
Specific CNVs at loci previously associated with psychiatric disorder
We tested whether CNVs in one of eight genomic regions that have previously been reported to be associated with neuropsychiatric disorders (1q21, 2p16, 7q34-36, 15q11, 15q13, 16p11, 17p12 and 22q11) were overrepresented in our BD patients. CNVs in these regions were not significantly overrepresented (Table 2) . However, the power of our sample to find significant association with these rare CNVs was low.
Pathways and biological processes impacted by CNVs in early-onset patients
To further characterize the two top association findings of our burden analyses in AOp21years patients (Table 1) , we used IPA to explore possible functional relationships between genes covered by either microduplications or singleton microdeletions. In the analysis of the 46 genes hit by singleton microdeletions, the significant first five top hits for biological processes (that's is, 'drug metabolism', 'lipid metabolism', 'molecular transport', 'small molecular biochemistry' and 'endocrine system development and function') were enriched by the presence of the genes SLCO1B1 and SLCO1B3, which are both located on 12p12. These were covered by a singleton microdeletion in one AOp21years patient. These categories were therefore omitted from data interpretation. Further top process categories that were significantly overrepresented due to several input genes being hit by singleton microdeletions included 'endocrine system disorder', 'genetic disorder', 'metabolic disease', 'immunological disease,' and 'infectious disease' ( Table 3 ). The same functional categories were found to be enriched when analyzing the 287 genes affected by microduplications in AOp21years patients (Table 4) , although there was no overlap in affected genes between the two gene lists, except for MAD1L1.
No significant result was obtained for canonical pathways in IPA after correction for multiple testing (data not shown). This was probably due to the limited number of genes introduced into the analysis.
Discussion
In the present study, we investigated a large sample of patients and controls of German descent for the [16] [17] [18] [19] [20] [21] [22] we also analyzed these subgroups separately. The basis for the statistical analyses was provided by highquality CNV prediction (QuantiSNP) using the SNP intensity data of 1 754 individuals and verification (PennCNV, visual inspection and TaqMan for specific CNVs). Parameters were specified to ensure that only relatively large CNVs (detected by X30 consecutive SNPs) with high statistical confidence (QuantiSNP: log Bayes factor X30; PennCNV: confidence value X30) passed QC. Using such stringent criteria is always a trade-off between sensitivity and quality of data. We have chosen our criteria to reduce type I error and are aware that this may lead to an increase of type II error at the same time.
Our genome-wide burden tests (RATE and PROP) provided no evidence that the overall number of singleton CNVs (both microdeletions and microduplications) overlapping with RefSeq genes was enriched in the total sample of BD patients compared with controls. The TOTKB and AVGKB tests demonstrated that the length of singleton microdeletions differed significantly between patients and controls (Table 1) . Singleton microdeletions in patients were approximately twice the size (487.6 kb) of those in controls (265.1 kb; AVGKB P = 0.014). Separate analyses of the AOp21years subgroup and the AO > 21-years subgroup demonstrated that this effect was mainly attributable to the AOp21years subgroup, in which the average size of microdeletions was 679.6 kb (AVGKB P = 0.0056), and to a lesser extent to the AO > 21years subgroup, in which the average size of singleton microdeletions (348 kb) was not significantly larger than in controls (AVGKB P = 0.17; data not shown). The most significant finding of our burden analyses was that the total number of patients with at least one microduplication (both common as well as singleton microduplications) was significantly higher in the AOp21years group, but not in the AO > 21years subgroup (PROP, P = 0.0004). The burden results suggest that both a higher CNV load and a larger CNV size are associated with BD in patients with an AOp21years. The effect in the earlyonset group was attributable to longer singleton deletions as well as to a higher frequency of microduplications (common and rare). Analysis of either the overall sample or the AO > 21years sample alone produced only marginal evidence that the genome-wide burden of CNVs has a role in disease development.
These results show a similar trend to those of Zhang et al. 12 who reported a significant overrepresentation of singleton deletions of more than 100 kb in their BD cases (16.2%) compared with controls (12.3%; P = 0.007). Interestingly, they also found that this effect was more pronounced in an early AO form of BD (age of mania onset p18 years). This is consistent with our observation of the presence of longer singleton deletions in early-onset BD patients. However, Zhang et al. 12 found no evidence of a higher frequency of microduplications in their early-onset mania subsample. Unfortunately, a more exact comparison of our data with that of Zhang et al.
12 is limited by the methodological differences between the two studies: Zhang et al.
12 used Affymetrix 6.0 arrays (Santa Clara, CA, USA) whereas we used Illumina HH550/H610Q arrays; Zhang et al. 12 performed CNV detection with Birdsuite whereas we used QuantiSNP and PennCNV; Zhang et al.
12 took all CNVs above a certain size threshold into account whereas we filtered for CNVs that overlapped with at least 30 consecutive SNPs and RefSeq genes.
Another recent study by Yang et al. 13 found no evidence for any significant association between the average number and size of CNVs and affective disorders (including BD and major depression). However, their study investigated a single threegeneration old order Amish family, and their main focus was upon the identification of CNVs that co-segregated with disease status across generations. The limited number of affected (n = 19) and unaffected family members (n = 32) and their genetic relatedness, as well as the broader phenotype definition used may have resulted in limited power to investigate the genome-wide burden aspects of CNVs in BD. CHRNA7, CLK4, COL23A1, COLEC12, CRYZ, CSMD1, CTH, CTSL1, CUL2,  CYFIP1, CYP2E1, DAPK1, DEPDC6, DGKB, DOCK4, DOCK8, DSCC1, E2F1,  EGFR, F2, FAT1, FOLH1, GDAP1, GLDC, GPC5, GPR115, GPR158, GPRC5C,  GRIP2, HYDIN, IMMP2L, JPH1, KCNE1, KCNE2, KCTD13, KDM4C, KIF25,  LILRA3, LILRB5, LYN, MAD1L1, MAMDC2, MLLT4, MPHOSPH6, MTHFD1L,  MTNR1A, NEGR1, NIPA1, NLRP12, NXN, NXPH1, PARK2, PDE8A, PDE8B,  PDPN, PLEKHG1, PPP1R9B, PRKCG, PSMF1, PTGER3, PTPRT, RBP3, RCAN1,  RETN, RNASE1, RSPO4, SEC61G, SLC22A23, SNX25, SPTLC3, SYT10, TAF2,  TAOK2, THOC1, TNR, TSPO, TTYH2, TUBGCP5, UPF3A, WDR41, YWHAE,  ZNF254, ZNF331, ZNF350, ZNF557, ZNF613, ZNF614, ABCA4, ACACB, ALKBH1, AMBRA1, APBA1, ATP10A, BTBD3, C14ORF166B,  CD36, CDC16, CDH12, CDH13, CHRNA7, CLK4, COL23A1, COLEC12, CSMD1,  CTH, CTSL1, CYP2E1, DAPK1, DEPDC6, DGKB, DOC2A, F2, FAT1, GLDC,  GPC5, GPR115, GPR158, HCP5, IMMP2L, KCNT2, KDM4C, KIF25, MAD1L1,  MAMDC2, MAZ, MICA, MLLT4, MTHFD1L, NEGR1, NXPH1, PARK2, PDE8A,  PDE8B, PTGER3, PTPRT, RCAN1, RETN, RSPO4, SYT10, TAF2, TAOK2,  TNR, ZNF350, , which investigated common and rare CNVs. They tested for association between BD and specific CNVs and CNVs at previously reported loci, as well as for genome-wide burden. Neither of these two studies found evidence for the involvement of CNVs in disease development. The majority of patients and controls investigated by Grozeva et al. 14 were also analyzed by the WTCCC, 15 and thus the results of the two studies are not entirely independent of each other. Major methodological differences exist between these two studies and our study, which hamper any direct comparison of the results. Firstly, different arrays were used to screen for CNVs (Grozeva et al.: 14 Affymetrix' Genechip Human Mapping 500 K Array Set; WTCCC:
15 Agilent Comparative Genomic Hybridization arrays). Secondly, Grozeva et al.
14 searched for rare CNVs (MAF < 1%) only, whereas the WTCCC 15 investigated common CNVs (MAF > 5%) only. The present study did not have any restrictions with regard to CNV frequency, and the frequencies of the two specific BD-associated CNVs on 10q11 (3.68% in controls) and 6q27 (2.53% in controls) are within a frequency range that was not investigated by Grozeva et al.
14 or the WTCCC. 15 Another important difference is the separate analyses of AO subgroups in the present study, which suggest that CNVs have a role in early onset, but not in later onset BD. As the aforementioned studies did not take AO into account, it is unclear whether such an effect was present in their BD samples. Nonetheless, all studies, including the present study, are in agreement that CNVs do not appear to influence BD when AO is not taken into account.
In a subsequent step of our genome-wide burden analysis, we performed an IPA to investigate whether the genes affected by microduplications (n = 287) or singleton microdeletions (n = 46) in AOp21years patients were significantly enriched for biological processes or pathways. When removing single genebased enriched categories, the top five significantly overrepresented biological function categories were the same for both the microduplications and the microdeletions gene lists, that is, the disorder and disease processes 'endocrine system disorder', 'genetic disorder', 'metabolic disease', 'immunological disease,' and 'infectious disease'. Follow-up studies in independent samples are clearly necessary to confirm that biological functions within these disease categories are involved in the pathophysiology of (early-onset) BD. One interesting gene with previous suggestive evidence for association with BD, mitotic arrest deficient-like 1 (MAD1L1, 7p22.3), was affected by a singleton microdeletion as well as a singleton microduplication in early-onset BD patients. Support for the involvement of this locus was provided by a recent GWAS of BD, 33 in which two MAD1L1 SNPs (rs11764590 and rs10278591; r 2 = 0.7) were the second and third best results in the meta-analysis step (P = 1.28 Â 10 À7 and P = 1.81 Â 10
À5
, respectively).
MAD1L1 is a mitotic spindle assembly checkpoint protein. Homozygous knockout of MAD1L1 in mice con fers embryonic lethality, indicating that MAD1L1 has an essential role during embryonic development. 39 Two genes affected by microduplications in early AO patients, epidermal growth factor receptor (EGFR, 7p11.2, one patient) and nucleoredoxin (NXN, 17p13.3, one patient, two controls), were identified as susceptibility genes for BD by two recent GWAS. 41, 42 Epidermal growth factor receptor rs17172438 (P = 3.26 Â 10
, OR = 1.32) and epidermal growth factor receptor rs729969 (P = 3.30 Â 10
, OR = 1.36) were ranked among the top 20 findings in the GWAS by Sklar et al. 41 Epidermal growth factor receptor and its ligands are cell signaling molecules that mediate diverse downstream cellular functions, including cell proliferation and differentiation. In a further GWAS, Baum et al. 42 found that NXN rs2360111 (P = 0.0003, OR = 1.23) were associated with BD. The NXN gene encodes the protein nucleoredoxin, which is involved in the inhibition of the WNT signaling pathway. 43 Another aim of the present study was to identify specific BD-associated CNVs. We found that the frequency of two relatively common CNVs on 6q27 and 10q11 differed significantly between patients and controls. Common microduplications located on chromosome 10q11 showed association in the overall sample (P = 0.035, OR = 1.53). Again, this effect was much stronger in the AOp21years subgroup (P = 0.00052, OR = 2.79). The other microduplication on chromosome 6q27 was overrepresented in the AOp21years subgroup (P = 0.0039, OR = 2.40), but not in the overall sample.
Interestingly, the 6q27 CNV region was implicated in BD in a three-generation old order Amish pedigree. 13 The 6q27 region was one of four regions that were enriched in affected pedigree members and which had an effect on the expression of genes within or near the rearrangement. The identification of the 6q27 region in two independent studies is clearly of interest, although further independent studies are required to support this finding. One limitation which prevents stronger conclusions being drawn from the Yang et al. study is that there was only modest co-segregation of the 6q27 CNV with BD. Thus the possibility that this relatively common variant segregated within the family independent of disease cannot be excluded.
In summary, the present study found evidence for a significant association between early AO BD and singleton microdeletions and microduplications. Although the frequency of microdeletions was not significantly higher in patients compared with controls, the size of singleton microdeletions was significantly larger. Our data also suggest that a higher frequency of microduplications is implicated in disease development. We found both the genomewide burden of microduplications as well as common specific microduplications on 6q27 and 10q11 to be enriched in BD patients. A further important finding of our study is that CNVs were strongly associated in patients with an AOp21 years, but not in patients with an AO > 21 years. In the overall BD sample, only a very weak association with CNVs was detected. Our results support for findings from previous clinical and formal genetic studies that early-and later-onset BD may represent genetically distinct forms of the disease. Future studies of CNVs in BD should therefore take the AO of their patient samples into account.
